News coverage about Novavax (NASDAQ:NVAX) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novavax earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.9097707867825 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

NVAX has been the topic of a number of recent analyst reports. Piper Jaffray Companies reaffirmed a “hold” rating and set a $1.50 price target on shares of Novavax in a report on Wednesday, July 26th. Zacks Investment Research downgraded shares of Novavax from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Chardan Capital reissued a “neutral” rating and issued a $1.50 price objective on shares of Novavax in a report on Thursday, July 27th. BidaskClub raised shares of Novavax from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Finally, Ladenburg Thalmann Financial Services raised shares of Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price objective on the stock in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $3.12.

Novavax (NASDAQ NVAX) opened at $1.29 on Friday. The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of -4.28. Novavax has a 1-year low of $0.73 and a 1-year high of $1.78.

Novavax (NASDAQ:NVAX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The company had revenue of $8.35 million for the quarter, compared to analysts’ expectations of $6.42 million. During the same quarter last year, the business earned ($0.24) EPS. The firm’s revenue was up 158.5% compared to the same quarter last year. equities research analysts expect that Novavax will post -0.62 EPS for the current year.

In other news, insider Stanley C. Erck bought 100,000 shares of the firm’s stock in a transaction on Thursday, November 9th. The shares were bought at an average price of $1.13 per share, for a total transaction of $113,000.00. Following the purchase, the insider now owns 228,279 shares in the company, valued at $257,955.27. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James F. Young sold 175,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total transaction of $185,500.00. The disclosure for this sale can be found here. 4.00% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Insider Buying and Selling by Quarter for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.